HotBoeing

Boeing to shift 787 production to ten-month cycle

Boeing announced it will begin transitioning its 787 Dreamliner production line to a ten-month rate this year.

Oct 27, 2026, 10:44 AM ETBA-9.5%

Illustration for the Business desk

The stocks in this story

BA-9.5%Boeing$170.38

Prices from Live · updated 11:51 AM ET. Each tile opens the stock's chart and news.

New to this? Read: Reading a stock chart

More Business news

HotAnthropic IPO

Anthropic IPO filing lifts chip stocks ahead of Boeing earnings

Futures point lower after Anthropic's IPO filing drove gains in chip stocks on strong first-half revenue. Boeing is set to report earnings before the market opens.

4:49 AM ETBA-9.5%

HotCintas UniFirst Merger

FTC reportedly plans to sue to block Cintas UniFirst merger

UniFirst shares fell 13.2 percent after reports indicated the FTC intends to challenge the $5.5 billion acquisition by Cintas. The gap between the stock price and the $310 offer widened to $77 as regulatory uncertainty grew.

10:28 AM ETUNF-8.2%CTAS-4.6%

AI Debt

Private equity adds AI disruption clauses to buyout loans

H.I.G. Capital included a provision in a $524 million loan for Terras Group that suspends default consequences if AI harms the business. Lenders rejected similar language in Bain Capital's $5.3 billion financing for Everllence.

9:47 AM ET

Deals

Robinhood and Ripple announce stablecoin and treasury partnership

The firms will integrate Ripple's RLUSD stablecoin and treasury tools across Robinhood's platforms, including Bitstamp. RLUSD is already live on Robinhood Chain, with app availability expected later in 2026.

9:27 AM ETHOOD+3.7%

BlueChip

Anduril and Qualcomm launch BlueChip laptop for military use

The rugged device features Snapdragon X processors made in Arizona and aims for 100 percent domestic sourcing. Preorders are set for 2027, with prices expected to be 20 percent higher than standard premium models.

9:17 AM ETQCOM+1.0%TSM+3.1%

Novartis

Novartis raises profit outlook despite drug development charges

Novartis booked $2.2 billion in charges for failed drugs, causing reported operating income to drop 61 percent. Core income rose 10 percent, prompting the company to lift its full-year profit forecast.

8:45 AM ETNVS+0.8%

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.